Press Releases
Connect Biopharma CEO to Attend as a Panelist at the CABS Investor Forum 2016 in San Francisco During the Week of the JP Morgan Healthcare Conference

Dr. Zheng Wei, Connect Biopharma CEO, is invited to attend the “CABS Investor Forum 2016” during the JP Morgan Healthcare Conference (January 11-15, 2016) in San Francisco, California. The Forum, focusing on investment in drug innovation in China, was organized by the Chinese-American BioPharmaceutical Society, ChinaBio, Morrison & Foerster, will take place on January 13, 2016 in San Francisco. Dr. Zheng Wei will participate as a panelist.

 

About Suzhou Connect Biopharmaceuticals

Suzhou Connect Biopharma discovers and develops novel immune modulators for the treatment of autoimmune diseases and inflammation. The company identifies and advances its drug candidates through internal discovery and in-licensing. Its lead program CBP-307 is an orally-active S1P1 agonist with best-in-class potential for the treatment of a wide range of autoimmune disorders including inflammatory bowel disease (IBD), psoriasis, and multiple sclerosis (MS). In addition, the company is advancing CBP-174, an in-licensed drug candidate for allergic inflammation; and CBP-201, an internally discovered monoclonal antibody for the treatment of asthma, eczema and other inflammatory diseases.


TEL/FAX: 0512-53577866

E-MAIL: qchang@connectpharm.com

ADD: Science and Technology Park, East R&D Building , 3rd Floor , 6 Beijing West Road, Taichang, Jiangsu, China 215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.

Technical support: Epower